Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Traynor

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2009
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II studyAnne M Traynor, Sarita Dubey, Jens C Eickhoff, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 4, 2026
Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cellsLauren Sarko, David Givand, Brendan Rattin, et al.
Journal of Clinical Medicine|January 8, 2023
Differential Effects of Patient Navigation across Latent Profiles of Barriers to Care among People Living with HIV and Comorbid ConditionsSharleen M Traynor, Renae D Schmidt, Lauren K Gooden, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 2, 2017
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Lakeesha L Carmichael, KyungMann Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network studySteven Attia, Anne M Traynor, Kyungmann Kim, et al.
Plos One|July 27, 2016
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1Jennifer L Schehr, Zachery D Schultz, Jay W Warrick, et al.
International Journal of Radiation Oncology, Biology, Physics|December 10, 2023
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b TrialMichael F Bassetti, Brett A Morris, Nan Sethakorn, et al.
Cancer|January 29, 2013
An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trialDavid H Gustafson, Lori L DuBenske, Kang Namkoong, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Investigational New Drugs|June 4, 2013
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II studyTien Hoang, Toby C Campbell, Chong Zhang, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 7, 2009
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II studyAnne M Traynor, Sarita Dubey, Jens C Eickhoff, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 4, 2026
Directing fratricide within T cell products using an anti-uPAR chimeric antigen receptor to drive the production of potent therapeutic cellsLauren Sarko, David Givand, Brendan Rattin, et al.
Journal of Clinical Medicine|January 8, 2023
Differential Effects of Patient Navigation across Latent Profiles of Barriers to Care among People Living with HIV and Comorbid ConditionsSharleen M Traynor, Renae D Schmidt, Lauren K Gooden, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 2, 2017
VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network StudyJulie E Chang, Lakeesha L Carmichael, KyungMann Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network studySteven Attia, Anne M Traynor, Kyungmann Kim, et al.
Plos One|July 27, 2016
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1Jennifer L Schehr, Zachery D Schultz, Jay W Warrick, et al.
International Journal of Radiation Oncology, Biology, Physics|December 10, 2023
Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b TrialMichael F Bassetti, Brett A Morris, Nan Sethakorn, et al.
Cancer|January 29, 2013
An eHealth system supporting palliative care for patients with non-small cell lung cancer: a randomized trialDavid H Gustafson, Lori L DuBenske, Kang Namkoong, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Investigational New Drugs|June 4, 2013
Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II studyTien Hoang, Toby C Campbell, Chong Zhang, et al.
Pageof 17